Community Bank’s Lineage Cell Therapeutics LCTX Stock Holding History

Community Bank’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-508	Closed	-$1K	–	461
2021 Q3	$1K	Buy	+508	New	+$1.3K	﹤0.01%	466

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Community Bank's LCTX Position: Q4 2021 in Review

Community Bank sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 508 shares — an estimated $1K sold.

Community Bank first reported a position in LCTX in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

Community Bank reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
Community Bank sold 508 Lineage Cell Therapeutics shares in Q4 2021, an estimated $1K.
Community Bank first reported a position in Lineage Cell Therapeutics in Q3 2021 and held it in 1 quarter.
Community Bank's Lineage Cell Therapeutics position peaked at $1K in Q3 2021.
124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on Community Bank's 13F filing for Q4 2021, filed 27 Jan 2022.